Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Leukemia, Myeloid, Acute
Bone Marrow Diseases
Chronic Myelomonocytic Leukemia
Novartis reference number
This study is Active, not recruiting.
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients, and to identify recommended doses for future studies.